| __timestamp | HUTCHMED (China) Limited | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 72049000 | 179279000 |
| Thursday, January 1, 2015 | 110777000 | 186359000 |
| Friday, January 1, 2016 | 156328000 | 171785000 |
| Sunday, January 1, 2017 | 175820000 | 208136000 |
| Monday, January 1, 2018 | 143944000 | 198405000 |
| Tuesday, January 1, 2019 | 160152000 | 224169000 |
| Wednesday, January 1, 2020 | 188519000 | 245044000 |
| Friday, January 1, 2021 | 258234000 | 252314000 |
| Saturday, January 1, 2022 | 311103000 | 268225000 |
| Sunday, January 1, 2023 | 384447000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. This analysis delves into the cost of revenue trends for HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, HUTCHMED's cost of revenue surged by over 430%, peaking at approximately 384 million in 2023. In contrast, Taro's cost of revenue increased by about 70% during the same period, reaching around 305 million. This stark difference highlights HUTCHMED's aggressive expansion strategy compared to Taro's more stable approach. Notably, 2024 data for HUTCHMED is missing, indicating potential reporting delays or strategic shifts. As these companies navigate the complexities of global markets, their cost management strategies will be pivotal in maintaining competitive edges. Stay tuned for more insights as we continue to track these industry leaders.
Cost of Revenue: Key Insights for Johnson & Johnson and HUTCHMED (China) Limited
Cost of Revenue Trends: AstraZeneca PLC vs HUTCHMED (China) Limited
Cost Insights: Breaking Down Pfizer Inc. and Taro Pharmaceutical Industries Ltd.'s Expenses
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited's Expenses
Cost of Revenue Trends: Viatris Inc. vs HUTCHMED (China) Limited
Corcept Therapeutics Incorporated vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Perrigo Company plc and HUTCHMED (China) Limited
Xenon Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: MorphoSys AG vs Taro Pharmaceutical Industries Ltd.
Cost of Revenue Comparison: HUTCHMED (China) Limited vs Xencor, Inc.
Cost Insights: Breaking Down Taro Pharmaceutical Industries Ltd. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Celldex Therapeutics, Inc.